Who are Onabotulinumtoxin A (BoNT)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): powder BoNT-A (BOTOX/Vistabel), Botulinum Toxin A (Botox ), Clostridium Botulinum Toxin Type A, Botulinum Toxin-A injection, Radiesse, Xeomin, Belotero, Botulinum Toxin Type-A (day 0).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/onabotulinumtoxin-a-bont.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Onabotulinumtoxin A (BoNT) — Competitive Intelligence Brief

Onabotulinumtoxin A (BoNT) (Onabotulinumtoxin A (BoNT)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin; botulinum toxin serotype A. Area: Neurology; Dermatology; Aesthetics.

marketed Neurotoxin; botulinum toxin serotype A SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology; Dermatology; Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

Onabotulinumtoxin A (BoNT) (Onabotulinumtoxin A (BoNT)) — Edgar LeClaire, MD. Onabotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Onabotulinumtoxin A (BoNT) TARGET	Onabotulinumtoxin A (BoNT)	Edgar LeClaire, MD	marketed	Neurotoxin; botulinum toxin serotype A	SNAP-25 (synaptosome-associated protein of 25 kDa)
powder BoNT-A (BOTOX/Vistabel)	powder BoNT-A (BOTOX/Vistabel)	Galderma R&D	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin A (Botox )	Botulinum Toxin A (Botox )	Assistance Publique - Hôpitaux de Paris	marketed	Neurotoxin; acetylcholine release inhibitor	SNARE proteins (specifically SNAP-25); acetylcholine release machinery
Clostridium Botulinum Toxin Type A	Clostridium Botulinum Toxin Type A	Daewoong Pharmaceutical Co. LTD.	marketed	Neurotoxin; botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin-A injection	Botulinum Toxin-A injection	Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust	marketed	Neurotoxin; neuromuscular blocking agent	SNARE complex (specifically cleaves SNAP-25)
Radiesse, Xeomin, Belotero	Radiesse, Xeomin, Belotero	Main Line Center for Laser Surgery	marketed	Dermal fillers and neurotoxin
Botulinum Toxin Type-A (day 0)	Botulinum Toxin Type-A (day 0)	Ivo Pitanguy Institute	marketed	Neurotoxin; neuromuscular blocking agent	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin; botulinum toxin serotype A class)

Edgar LeClaire, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Onabotulinumtoxin A (BoNT) — Competitive Intelligence Brief. https://druglandscape.com/ci/onabotulinumtoxin-a-bont. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab